Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,241 matching trials from the live ClinicalTrials.gov search.
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Ashwagandha Pharmacokinetics Study in Older Adults

NCT06171724
Conditions
Healthy, Aging
Interventions
Shoden
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
65 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Parkinson's Disease (PD), Essential Tremor
Interventions
Phoneme sequence learning, Cessation and re-enabling of stimulation of the STN, Cessation and re-enabling of stimulation of the VIM thalamic nucleus, Multisyllabic sequence learning
Behavioral · Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat Tablets in Healthy Adults

NCT05284760
Conditions
Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tempe, Arizona
Completed No phase listed Observational Accepts healthy volunteers

Indocyanine Green Tissue Perfusion Monitoring

NCT02978560
Conditions
Regional Blood Flow, Wound Heal
Interventions
fluorescence-mediated photoplethysmography
Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Towson, Maryland
Conditions
Healthy Volunteer
Interventions
RO5424802, rifampin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Conditions
Epilepsy
Interventions
Divalproex Sodium Extended-release 250mg, DEPAKOTE 250mg
Drug
Lead sponsor
Vince & Associates Clinical Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
HIV
Interventions
Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet), Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel), Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older · Male only
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Enrolling by invitation No phase listed Observational

CrCest Study in Primary Mitochondrial Disease

NCT04734626
Conditions
Mitochondrial Diseases
Interventions
Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
7 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Healthy Participants
Interventions
Oral [14C]PF-06865571, Oral PF-06865571, IV [14C]PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
COVID-19
Interventions
albuterol sulfate (MDI), albuterol sulfate (nebulizer)
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Acquired Hemophilia A
Interventions
OBIZUR
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 13 more
Conditions
Healthy Study Participants, Participants With Mild Asthma
Interventions
Alprazolam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
North Dartmouth, Massachusetts • Raleigh, North Carolina
Conditions
Chronic Pain
Interventions
Spinal cord stimulator
Device
Lead sponsor
The Center for Clinical Research, Winston-Salem, NC
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Healthy Volunteers
Interventions
Teduglutide, Syringe Injection, Pen injector
Drug · Device
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Not applicable Interventional Results available

NICU Oxygen Control Study

NCT04269161
Conditions
Hyperoxia, Hypoxia
Interventions
Automatic control of inspired oxygen
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Pensacola, Florida • Columbia, Missouri
Conditions
Healthy Volunteer
Interventions
varegacestat, Itraconazole (200 mg)
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Daily Disposable Toric Soft Lenses Manufactured With an Alternative Hydration Process

NCT06967129
Conditions
Astigmatism
Interventions
Investigational daily disposable, soft, toric lenses manufactured on 4th Generation Technology (4GT) lines with extended mini-stack hydration using propylene glycol (PG) as the hydration solvent., ACUVUE® Oasys 1-Day for Astigmatism (AO1DfA) soft contact lenses manufactured on 3rd Generation Technology (3GT) legacy lines using isopropyl alcohol (IPA) as the hydration solvent.
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
20
States / cities
Mission Viejo, California • San Diego, California • Jacksonville, Florida + 16 more
Conditions
Anesthesia Induction Ventilation
Interventions
Tao Mask, Standard Mask
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine Thorough QT/QTc

NCT00543062
Conditions
Cardiotoxicity
Interventions
Inhaled placebo, Oral placebo, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Oral moxifloxacin
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Solid Cancer, Metastatic Spinal Lesions
Interventions
Dynamic contrast enhancement MRI
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Tobacco Use
Interventions
Test Product A, Test Product B, Test Product C, Test Product D, Test Product E, Reference Product F: Subjects' OBMST
Other
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Bentonville, Arkansas • Springfield, Missouri
Conditions
Healthy
Interventions
Seltorexant 40 mg, Seltorexant 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Unprotected Sex, Contraceptive Usage
Interventions
Pulse
Behavioral
Lead sponsor
Child Trends
Other
Eligibility
18 Years to 20 Years · Female only
Enrollment
2,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland